Kiadis Poised To Launch Lead Product ATIR101 In 2019
Launch approval of Netherlands-based Kiadis Pharma's lead asset ATIR101 looks likely in Europe by early-2019 for safer, more effective bone marrow transplants. US approval will take longer.
You may also be interested in...
October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.
A Phase III clinical trial comparing AbbVie's Skyrizi with Novartis's IL-17 agonist Cosentyx showed the former's superiority in adults with moderate-to-severe plaque psoriasis.
Acasti’s omega-3 candidate drug CaPre missed the primary endpoint in TRILOGY-1 due to an unexplained high placebo effect, as AstraZeneca said its STRENGTH study was unlikely to show a treatment benefit.